China MOH Releases 2008 Catalogs Of Centralized Purchasing For Medical Consumables
This article was originally published in PharmAsia News
Executive Summary
China's Ministry of Health has published the 2008 candidates' product catalogs for the national centralized purchasing of high-value medical consumables (PharmAsia News, Aug. 11, 2008), with the details posted on its International Communication and Cooperation Center website. MOH requires all regions to execute the purchase from Oct.1, within a one-year purchasing cycle. China's urban health care institutions' expenditure on medical consumables increased at an annual rate of 22.4 percent from RMB 9.693 billion ($1.417 billion) to RMB 39.831 billion ($5.825 billion) between 2000 and 2007, far exceeding drug expenses. Experts reveal that the government plans to include all medical devices into centralized purchasing by 2010. The country's increased investment of RMB 150 billion in public health and government purchase, with priority for local brands, will boost the domestic medical devices industry. (Click here for more - Chinese Language)
You may also be interested in...
China Conducts First Centralized Purchasing For Medical Consumables
China's Ministry of Health has successfully conducted the 2008 national centralized purchasing of high-value medical consumables, at an average 10 percent lower rate. The first such exercise to supply medical institutions nationwide, the products purchased are classified into four categories: cardiac pacemaker, electrophysiology, cardiac intervention and peripheral vascular intervention (neurological intervention). MOH will publicize candidates' product catalogs and pricing in the near future. Non-profit medical institutions across the country may purchase these items; in principle, they should not buy similar products outside the catalog. Experts point out that the centralized purchasing can unify pricing of different regions in China, paving the way toward formulating standardized charging for medical care services. (Click here for more - Chinese Language)
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.